A Promising Option for Diffuse Large B-Cell Lymphoma
- Bispecific antibodies are a unique targeted therapy that essentially attack cancer on two fronts — and recent approvals mean more patients have access to the innovative treatment option.
- Currently, two drugs have been approved by the FDA to treat diffuse large B-cell lymphoma: Glofitamab (Columvi) and Epcoritamab (Epkinly).
- The drugs “are really showing quite striking efficacy and a manageable safety profile in patients who’ve had at least two prior lines of treatment,” Dr. Loretta Nastoupil, an oncologist at MD Anderson Cancer Center, tells SurvivorNet.
- Dr. Nastoupil notes that trials are now looking into using the drugs at earlier points during treatment.
Bispecific antibodies are a unique targeted therapy that essentially attack cancer on two fronts — and recent approvals mean more patients have access to the treatment option.
Read More- Glofitamab (Columvi)
- Epcoritamab (Epkinly)
Bispecific Antibodies: The Future
The fact that bispecific antibodies are now FDA approved is a big deal when it comes to treating lymphoma, Dr. Nastoupil notes, as they were not approved as recently as a year ago.
“Now, those newer therapies are quickly marching their way into earlier lines in the form of trials,” she notes. “So, maybe next year or two years from now, [patients will] even have access to those maybe as their first treatment approach.”
If you’re looking for innovative treatment options currently in the clinical trial phase, check out SurvivorNet’s simple Clinical Trial Finder.
Learn more about SurvivorNet's rigorous medical review process.
